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1. Introduction  
This chapter will deal with the present role of Liver Biopsy in determining liver disease 
prognosis in hepatitis B and C patients on haemodialysis and its role in establishing 
treatment strategies and in the decision-making process prior to kidney transplant. In recent 
years, progress has been made in determining the natural history of this disease in renal 
patients (Espinosa et al., 2004; Jadoul et al., 2004). 
Chronic hepatitis due to HCV is frequent in renal transplant recipients and in dialysis 
patients and has a significant impact on their survival (Hanafusa et al., 1998; Orloff et al., 
1995; Pouteil-Noble et al., 1995). Mathurin et al., (1999) demonstrated in a case-control study 
that anti-HCV and HBsAg positive were independently associated with patient and graft 
survival. This was the first time that a 10 year follow-up was carried out; previous 
publications are based on shorter follow-ups and fewer patients. 
It is known that the prevalence of chronic infection with the hepatitis C virus (HCV) in 
patients with chronic kidney disease is higher than in the general population (Lavanchy, 
2009). The estimated prevalence of chronic infection in haemodialysis patients is 13%, 
ranging from 10 to 65 %, depending on the geographical zone (Hmaied et al., 2006; Huraib 
et al., 1995; Santos & Souto, 2007; Shamshiraz et al., 2004). 
When considering patients candidates to kidney transplantation we have to take into 
account that immunosuppressive therapy after renal transplantation predisposes a 
reactivation of chronic viral hepatitis B or C, which is usually a mild disease for patients 
remaining under haemodialysis.  
It should be noted that HBV and HCV may induce de novo glomerulonephritis and chronic 
allograft nephropathy which can lead to graft failure (Aouifi & Garcia, 2001). In such cases, 
patients have to undergo dialysis again and therefore it is beneficial to eradicate HCV RNA 
before transplantation and to control and maintain HBV DNA negative (Huskey & 
Wiseman, 2011). 
A routine liver histological analysis could improve a patient’s chance of being selected for 
renal transplantation. Liver biopsy has been considered the “gold standard” for many years, 
because it provides us with information that was otherwise unobtainable (Ghany et al., 
2010). Nowadays however, due to progress in non-invasive methods, liver biopsy is only 
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necessary in selected cases or in patients with a lack of correlation between clinical and 
analytical data (Alric et al., 2009; Stasi et al., 2009).  
In solid organ transplant patients, who are HBV or HCV carriers under 
immunosuppressives, an increasing frequency of fibrosing cholestatic hepatitis has been 
described. This type of hepatitis evolves rapidly to liver cirrhosis, significantly increases 
morbidity and mortality and leads to the need for a liver transplantation in selected cases 
(Boletis et al., 2000; Delladetsima et al., 1999; Vallet-Pichard et al., 2011). (Table 1). 
 
Typical viral hepatitis Fibrosing cholestatic hepatitis 
- Portal lymphocytic infiltrates are 
observed, with various degrees of 
periportal interface inflammatory 
activity. 
- Lobular necroinflammatory change is 
present, the inflammatory component 
chiefly lymphocytic. Granulomatous 
hepatitis, have been reported in chronic 
HCV infection. 
- Different morphologic changes are 
specifically seen in particular 
hepatotropic virus:  
a. HCV: Portal lymphoid aggregates 
and follicles, focal duct damage, 
and mild fatty change often occur. 
b. HBV: “Ground glass” cells and 
sometimes mild fatty change may 
be seen. 
 
- Described in patients under 
immunosuppressors and related to a 
direct viral cytopathic effect on the liver 
cells and although fibrosing cholestatic 
hepatitis is seen in both  HBV and HCV 
infection, it is more common in the 
former.  
- Portal expansion with periportal and 
intrasinusoidal collagen deposition, bile 
ductular proliferation, but with minimal 
portal inflammation are seen. 
- Prominent ballooning change of liver 
cells occurs, with associated cholestasis 
but mild lobular inflammation. 
- Variable but sometimes prominent fatty 
change (steatoviral) may occur.  In 
severe cases, bridging and multiacinar 
necrosis can be seen, leading to the graft 
failure. 
Table 1. Chronic Hepatitis major morphologic features. Typical viral hepatitis vs  Fibrosing 
cholestatic hepatitis. (Adapt., Kanel, G. C. & Korula, J.  (2011) Atlas of Liver Pathology, 
Elsevier Saunders, ISBN: 978-1-4377-0765-6) 
2. General approach 
2.1 Preliminary considerations 
Active HCV infection in dialysis patients, namely HCV-RNA positive by PCR, requires 
evaluation of liver fibrosis preferentially by liver biopsy. New tools for assessing fibrosis by 
non-invasive methods have been developed, and although they have yet to be validated for 
chronic kidney patients they will be discussed in this chapter.  
General management of chronic viral hepatitis and in particular the indication of liver 
biopsy, in a practical clinical approach, has the objective to avoid liver-related mortality and 
to promote allograft survival in kidney transplanted patients (Sezer et al., 2004). 
2.2 Historical background  
Over the past few decades, medical progress has been made and new specialities have 
emerged in areas such as solid organ transplants and chronic viral hepatitis treatments. 
Nephrology and hepatology specialities have to plan an interdisciplinary care approach for 
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patients candidates for transplantation and for those receiving immunosuppressors 
especially in hepatitis virus carriers (Fabrizi et al., 2010a, Carriero et al., 2008). 
One quarter of HCV positive patients evaluated for a kidney transplant have advanced 
fibrosis or cirrhosis in the liver biopsy. In the past they should require a combined liver and 
kidney transplant. Currently, this concept is not fully accepted, for the following two 
reasons:  
1. Due to the scarcity of donors some patients with cirrhosis or advanced liver fibrosis, but 
never decompensated, are being accepted for renal transplantation only . 
2. Liver biopsies, which were mandatory several years ago, are being replaced by non-
invasive methods in mild or severe hepatitis. However, patients diagnosed inconclusively 
must undergo a liver biopsy to confirm the diagnosis (Sebastiani & Alberti, 2006).  
2.3 Our experience 
In 1991 we initiated a prospective, non-randomized study to assess the tolerability and 
efficacy of Interferon (IFN) alfa for treating chronic hepatitis C in kidney transplant 
candidates undergoing haemodialysis. The aims were to evaluate the efficacy and safety of 
IFN alfa in this setting. We studied HCV RNA status at the end of treatment and during 
follow-up and the complications related to haemodialysis, to primary renal disease, and to 
the use of IFN during treatment. We also studied the evolution of the kidney graft in 
transplanted patients and the evolution of hepatitis after transplantation to investigate the 
risk of accelerated liver disease. It should be noted that although we now evaluate the 
results of the anti-virals with viral kinetics, at the begining of the study PCR qualitative of 
RNA-HCV was the only available method. 
This study was published in 2001, and the results showed that 64% had Sustained Viral 
Response (SVR) and HCV-RNA was repeatedly negative during the follow-up (Casanovas-
Taltavull et al., 2001). Moreover a lesser development of de novo glomerulonephritis was 
observed in patients to whom IFN alfa had been administered (Cruzado et al., 2003). 
We have to take into account that in those days our dialyzed patients had a higher 
prevalence of viral hepatitis. The prevalence of HBV and HCV infections has markedly 
decreased in patients who are candidates for transplantation since the introduction of 
screening, hygiene and prevention measures, including systematic vaccination against HBV, 
screening of blood and organ donations, use of erythropoietin, compliance with universal 
hygiene rules, and isolation of HBV-infected and HCV positive patients from non-infected 
patients (Fabrizi et al., 2004).  
Blood transfusions were common in the past because they were thought to improve graft 
tolerance and erithropoietin had yet to be approved for this indication (Light et al., 1982). 
While an anti-Hepatitis B vaccine is indicated in these patients, an anti-HCV vaccine has yet 
to be developped. Preventive and general measures are therefore crucial for stopping viral 
transmission (Sauné et al., 2010). 
3. Clinical spectrum and natural history of the disease 
3.1 Epidemiology and prevalence of liver diseases in patients under substitutive renal 
treatment  
Reports on the natural history of hepatitis C infection in the dialysis population vary and 
consequently is not completely understood. The slow progression of the HCV-associated 
liver disease may mask the consequences of HCV infection in the dialysis population (Okoh 
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et al., 2008). Previous studies that focused on liver disease demonstrated a low proportion of 
HCV-positive dialysis patients with bridging hepatic fibrosis or cirrhosis (Gane & Pilmore, 
2002). 
The possible explanation for such a distinct difference is a reduction of the viral load via 
adsorption of viral particles with their subsequent destruction (Kaiser et al., 2008). In the 
same way, alanine aminotransferase (ALT) may be filtered through the dialyser membrane 
and ALT levels may be normal in patients with otherwise advanced liver disease (Lopes et 
al., 2006). 
Because of the persisting contradictions reported, there is an urgent need for better 
communication between specialists to establish clear guidelines for the management of 
chronic viral hepatitis in ESRD patients.  Phase 3 trials of new antivirals, in combination 
with pegIFN and ribavirin in the general population, which have a primary end point of 
SVR efficacy, are expected to be performed. Before administering these new drugs  to 
patients under hemodialysis  it will be necessary to perform PK studies  and to obtain a 
toxicological profile  of these new drugs in this setting. 
3.2 Risk factors (Table 2) some concerns  
Studies on viral isolates have suggested a nosocomial patient-to-patient transmission of HCV 
infection among dialysis patients in some centers despite dialysis centers having routine 
protocols to prevent hepatitis transmission and to control the infection (McLaughlin et al., 
1997). Several dilemmas regarding the management of these patients have yet to be resolved:  
1. Should HCV-RNA testing and complete HBV serologies be included in the routine 
screening of HD population for chronic hepatitis infection, considering the fact that 
anti-HCV remains positive even in cured patients and that in some RNA-HCV positive 
cases, antibodies may be negative (“occult-hepatitis”) (Angelico et al., 2000). 
2. Does periodic serum ALT testing have a role in HD patients for hepatitis infection 
although it is known that ALT may be normal in this population?  
3. Should HCV or HBV-infected subjects be isolated and dialyzed by segregated 
machines? This situation is not totally resolved and can lead to misunderstandings 
among medical teams and cured patients. 
 
Intravenous drug use 
Number of blood transfusions received before 1999 
Duration of hemodialysis 
Mode of dialysis 
Prevalence of HCV infection in the dialysis unit 
Previous organ transplantation 
Male gender / Older age 
Intravenous drug use 
Previous HBV infection 
General risk of nosocomial transmission of HCV 
Table 2. Risk Factors for HCV infection in dialysis patients (Alavian, S. M., 2009). 
3.3 Impact of transplantation on the natural history of hepatitis                                                                
Renal Transplantation is recognized as the treatment of choice in most patients with end 
stage renal disease but the decision-making process for kidney transplant in hepatitis cases 
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is complex. Recently, however, it has been shown that clinical evolution is better in patients 
who have received a kidney transpant, even in those who are non responders to antivirals, 
than in patients who have to remain under haemodialysis. (Sezer et al., 2004).  
3.4 Hepatitis B virus (HBV) in renal patients                                                                                              
Although the prevalence of hepatitis B virus (HBV) infection has declined in haemodialysis 
patients and in renal transplant recipients, it remains high within countries with endemic 
HBV infection (especially Asia-Pacific and Africa). Renal transplantation is associated with 
reduced survival in HBsAg+ hemodialysis patients (Aroldi et al., 2005).                                                               
Treatment of hepatitis B is indicated among kidney transplanted patients and haemodialysis 
patients with HBV in replicative phase, (same indications as the general population) but the 
anti-HBV treatment has to be pursued as a preventive measure once the patient has received 
the transplant in order to avoid progression of the liver disease which could affect the liver 
and also the graft (Daudé et al., 2011).                                                                                
Lamivudine used to be the only option for such cases but severe forms of exacerbation were 
described due to resistant mutants. Present anti-HBV therapy based on nucleos(t)ide 
analogues, such as tenofovir or entecavir, are now recommended. They are more potent, 
have a higher genetic barrier than lamivudine and are well tolerated. The dosing and 
administration depends on the creatinine clearance (Vigano et al., 2005).                                                              
Treatment with entecavir or tenofovir is indicated in all HBsAg-positive candidates for 
transplantation and after transplantation in order to maintain HBV DNA negative. Better 
graft survival has been described in HBsAg negative patients in comparison with patients 
with HBV infection (HBsAg positive or only anti-HBc positive) undergoing 
immunosuppressor treatment (Gane & Pilmore, 2002). 
A liver biopsy in HBV positive patients has to be considered when image test results, such 
as ultrasound echography or fibroscan, are unclear or misleading and if there is no 
correlation between clinical and analytical data. A three phase liver CAT (Computed Axial 
Tomography) scan with injection of contrast medium is indicated when an ultrasound 
echography detects signs of a possible tumour. 
Whatever the baseline histological evaluation, with the new anti-HBV anti-virals, sustained 
suppression of necro-inflammation may result in regression of fibrosis or cirrhosis, which in 
turn may lead to decreased disease-related morbidity and improved survival (Vallet-
Pichard et al., 2011). Regular monitoring with liver function tests and HBV DNA 
measurements should enable early detection and rescue in case of appearance of 
demonstrated virus resistance. 
3.5 Hepatitis C virus (HCV) in renal patients  
We consider that haemodialysis patients (presenting no severe co-morbidities or contra-
indications) are candidates to anti-HCV treatment only if they are being evaluated for the 
waiting list for kidney transplant and as long as they have no contraindications to interferon 
therapy, because the evolution of hepatitis C is generally mild for patients remaining on 
dialysis (Kidney Disease Improving Global Outcomes [KDIGO], 2008). 
Although anti-HCV treatment must be proposed to all candidates for renal transplantation 
who had no contraindications to interferon, whatever their baseline histopathology, in 
HCV-infected patients undergoing chronic dialysis who are non-candidates for renal 
transplantation, the indication for antiviral therapy has to be individualized and is usually 
limited to patients with significant fibrosis (Gordon  et al., 2009).  
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After transplantation, interferon- α is contraindicated but may be used in patients for whom 
the benefits of antiviral treatment clearly outweigh the risks, especially that of allograft 
rejection. Due to this risk, dialysis patients recieving anti-viral treatment are taken off the 
waiting list.                                                                  
Questions about efficacy and safety of HCV treatment have yet to be resolved because 
practice and guidelines accepted for the general population cannot be applied to dialysed 
cases. These patients are considered as a special population and the treatment is only 
indicated for selected cases after weighing the pros and cons. Sustained viral response rates 
as high as 50 to 60% have been demonstrated with interferon monotherapy in dialysis 
(Fabrizi et al., 2008; Fabrizi et al., 2010a). 
The therapeutical anti-viral option with pegylated interferon was incorporated in 2000 to the 
protocols for HCV treatment and adopted for the management of dialyzed patients due to 
its positive results and because it requires only one injection a week. Previously, standard 
interferon was administered three times weekly after every dialysis session. Currently, the 
question of whether results with pegylated interferon are better than those observed in the 
past with standard interferon remains unanswered. Ribavirine was totally contraindicated 
in uremic patients, but due with a better sustained response to anti-HCV treatment obtained 
with the combination of pegilated interferon and ribavirine in the general population, it now 
has a role in the HCV treatment in patients undergoing dialysis (Fabrizi et al., 2010b). 
Concerns about its use are present due to the risk of severe anemia in this setting. 
Combining ribavirine in uremic cases has only been accepted with extreme caution 
regarding doses, recommending only 200 mg, 1 pill a week. In the event of good tolerance 
the dose may be increased to 2-3 pills weekly, always combined with erythropoietin 
(Carriero et al., 2008). 
Treatment of chronic HCV infection with pegylated interferon and ribavirin in kidney 
transplant recipients is associated with a risk of acute or chronic cellular rejection of 30% or 
more, resulting in graft loss and reduced patient survival. Therefore, indications for 
treatment must be tailored accordingly. The indication should be assessed on a case-by-case 
basis, if HCV infection is life-threatening. 
Hepatitis C virus (HCV) infection influences glomerular pathologic findings in renal 
allografts and affects the graft outcome. In diagnostic renal allograft biopsies, after kidney 
transplant, the presence of de novo immune-mediated glomerulonephritis has been 
observed, especially type I membrano prolipherative glomerulonephritis (MPGN), which is 
strongly associated with HCV infection and results in accelerated loss of the graft. Cruzado 
et al., (2003) proved that patients previously treated with interferon were less at risk of 
developing MPGN. 
4. Diagnostic procedures  
4.1 Serological assays and blood liver tests 
The assessment of liver disease should include biochemical markers, such as alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), gamma-glutamyl 
transpeptidase (GGT), alkaline phosphatase, bilirubin, prothrombin time or INR 
(International Normalized Ratio); albumin; gammaglobulins and full blood counts. 
Abdominal ultrasound should be obtained as  basic hepato-biliary imaging (Kidney Disease 
Improving Global Outcomes [KDIGO], 2008).  
Various serological assays are available for the diagnosis and follow-up of HCV infection. 
Third generation serological tests for determining the presence of HCV antibodies are 
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highly sensitive and specific. In case of positive serology, viral load should be determined 
by HCV RNA. In addition, quantitative real time PCR should be determined at least once in 
each patient in order to diagnose cases that have ‘escaped’ lower-sensitivity tests (Angelico 
et al., 2000). 
ALT, as mentioned previously, is a helpful, although non-specific, marker of the presence of 
HCV infection in the dialysis population. Serial determinations of ALT are vague when 
reflecting the severity of liver disease and do not correlate with the liver histology or viral 
load (Lopes et al., 2006). 
According to our experience, all patients with end-stage renal disease should undergo 
serological tests to screen for HCV and HBV and have their status confirmed by PCR before 
starting renal replacement therapy (hemo-dialysis, peritoneal dialysis). 
4.2 Non-invasive imaging techniques  
The ideal non-invasive test has to be simple and reproducible, readily available, easy to 
perform, less expensive than biopsy, and able to predict the full spectrum of fibrosis and to 
reflect changes occurring over time (Gaiani et al., 1997; Lackner et al., 2005).  
The majority of studies have focused on HCV cases, the most prevalent liver disease in the 
general population, but there are few studies addressing chronic kidney patients under 
dialysis treatment (Alric et al., 2009).  
Non-invasive methods include blood/serum markers and imaging/scanning techniques. 
Ultrasonography and Elastography (Fibroscan) combined with blood indexes, are the most 
reliable for detecting  liver cirrhosis. However, in kidney patients their clinical use is limited 
because they have not been totally validated. This is a developing field and in the future a 
combination of data will probably be available in order to establish prognosis and diagnosis 
of cirrhosis.  
4.2.1 Blood tests to diagnose chronic liver disease 
Fibrosis assessment in research is done with serum fibrosis markers which can be divided 
into direct and indirect markers, with a preference for indirect markers. 
a) Direct markers are involved in the formation of an extracellular matrix during fibrosis, 
and indirect markers reflect hepatic dysfunction. Several studies on the diagnosis of liver 
cirrhosis using direct fibrosis markers, such as collagen and hyaluronic acid, had a low 
sensitivity and specificity (approximately 80%). Fibrosis markers are expensive and not 
available for clinical practice. 
b) Indirect fibrosis markers include the AST-to-ALT ratio (AAR), the AST-to-platelet ratio 
index (APRI), and Forns's index (Forns et al., 2002) which is the most popular as it enables 
the required data to be obtained easily. 
Sebastian et al. (2009) have published results showing that combining the results of 
fibroscan and blood tests may reduce the indication of liver biopsy. In clinical practice 
diagnosis of compensated cirrhosis is based on ultrasonography and routine blood tests.  
4.2.2 Ultrasonographic (US) imaging   
Ultrasonographic (US) imaging with Doppler analysis is being widely used for the diagnosis 
of chronic hepatitis and compensated and decompensated cirrhosis. 
US is safe, inexpensive, and routinely used within hospitals, it is also available in individual 
doctor’s practices and in mobile settings. It offers real-time capability without the need for 
much data processing and analysis. However, it is recognized that the US technique needs a 
skilled operator, which is an important drawback.  
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The combination of gray scale US and Doppler US improves diagnostic accuracy and is 
essential for diagnosis of cirrhosis or fibrosis. It is known that liver fibrosis and steatosis can 
have similar appearances and can be present at the same time in a ‘‘fatty-fibrotic pattern” 
(Borrioni et al., 2006). US can show a small, nodular liver in advanced cirrhosis, but surface 
nodularity or increased echogenicity can be seen in hepatic steatosis as well as in cirrhosis 
(Hirche et al., 2007). 
 
    ADVANTAGES   DISADVANTAGES 
Liver biopsy  
 Great experience  
 Evaluates other parameters in 
addition to fibrosis  
  Accurately differenciates 
varying stages of fibrosis 
 Sampling errors  
 Varies depending on the 
observer's interpretation  
 Invasive method (morbidity 
and mortality)  
 Hospitalization required  
 Expensive 
Hepatic Elastography  
(Fibroscan) 
 Good reproductibility  
 More comprehensive 
assessment of liver tissue  
 Non-invasive method  
 Does not require admission  
 Inexpensive 
No experience in dialysis 
patients  
Less applicable if obesity, 
ascites, or/and small intercostal 
spaces  
Unreliable fibrosis results if 
cholestasis, cytolysis or liver 
edema  
 Only evaluates fibrosis  
 Does not discriminate between 
intermediate stages  of fibrosis 
 
Table 3. Theoretical advantages and disadvantages of liver biopsy and hepatic transient 
elastography  of the liver in patients on dialysis, providing the lack of validation studies.  
Gaiani et al., (1997) investigated the accuracy of an ultrasonographic score derived from 
liver, spleen, and portal vein features in predicting the final diagnosis in patients with 
compensated chronic liver disease. After comparing results obtained by ultrasonography to 
those obtained by percutaneous liver biopsy, they identified liver surface nodularity and 
portal flow velocity as factors independently associated with cirrhosis. Enlargement of the 
caudate lobe and spleen size besides the specific echogenicity pattern have been found to be 
associated with cirrhosis in other studies. Spleen size was assessed longitudinally and 
considered normal up to 12 cm.  
A model consisting of liver surface nodularity obtained by echography, may be useful for 
the identification of compensated cirrhosis with a high degree of accuracy in daily practice, 
when a platelet count of less than 100,000/mm3, an albumin level of less than 3.5 g/dL, and 
a prothrombin time or an INR of more than 1.3, is observed. 
Albumin and prothrombin time or INR indicate the synthetic activity of the liver and 
platelet count reflects the degree of portal hypertension. As these variables, excepting the 
platelet count, are used in the Child-Pugh scoring system, the most used classification for 
cirrhosis prognosis, the specificity of the items appears to be high. 
The albumin level and INR has more than 95% specificity in identifying cirrhosis, but 
sensitivity is low. A platelet count of less than 100,000/ mm3 has been widely accepted as 
the cut-off level of portal hypertension.  
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With strengths and limitations, the usual blood tests and ultrasonographic variables are the 
basis for the diagnosis of compensated liver cirrhosis (Fontana & Lok., 2002; Sebastiani et al., 
2006). 
4.2.3 Hepatic elastography (fibroscan)  
The fibrogenic evolution of chronic viral hepatitis B and C towards cirrhosis represents a 
key issue in clinical hepatology. Traditionally, liver fibrosis has been assessed by liver 
biopsy. One of the most important reasons for which a liver biopsy has been indicated in 
many situations including patients with chronic renal failure and viral hepatitis is fibrosis 
assessment. The liver biopsy has a low although non-negligible morbidity and mortality 
rate. 
The fragment of liver tissue studied is small and represents only 1/50.000 of the liver. Liver 
biopsy obtains a semiquantitative result leading to a possible inaccurate fibrosis assessment, 
because fibrosis is heterogeneously distributed. Furthermore, the evaluation of the specimen 
requires an experimented pathologist to give his/her diagnostic opinion. There may 
therefore be cases of inter or intra-observer variations. Some studies show that there can be 
differences of up to 35% variability and of up to 20% interobservational, which can lead to 
errors when studying the hepatic fibrosis of a particular patient (Standish et al., 2006).  
In the past ten years, non-invasive methodologies have been proposed to predict the 
presence of fibrosis in chronic liver disease, especially the introduction of transient 
elastography or FibroScan ® (Castera et al., 2005; Ziol et al., 2005) which represents a further 
advancement. 
This technique is based on the estimate of liver tissue elasticity by ultrasound. This is done 
by measuring the speed of propagation of a mechanical wave within the liver parenchyma. 
Results, expressed in kilo Pascals, are obtained from the speed of the recorded wave (meters 
/ second).  Hepatic elastography provides a number of advantages compared to liver biopsy 
(Table 3).  
The evaluated tissue volume is about 100 times bigger than the biopsy which is therefore 
likely to be much more representative of the total liver tissue. As it is non-invasive, this  
method  can  be repeated in the same patient. It has also shown good reproducibility 
between observers. Nevertheless, this technique also has its limitations. In 5-15% of patients 
it is impossible to use because of its inability to pass the mechanical wave and to reach the 
liver in obese patients and in patients with small intercostal spaces or due to the presence of 
ascites. Furthermore, some situations or comorbidities of the patient may produce unreliable 
results of this test. This can occur if there is liver stasis, marked elevation of transaminases 
or a presence of significant cholestasis. Hepatic elastography has demonstrated a high 
sensitivity and specificity enabling a correct diagnosis of fibrosis even when cirrhosis is 
already present, but this method is not as efficient for classifying intermediate fibrosis 
stages. Establishing the exact stage of fibrosis can be improved by using hepatic 
elastography in conjunction with fibrosis serum markers or the fibrotests mentioned above. 
Fibroscan has proved its utility in diverse liver diseases (chronic HCV or HBV, NASH, 
sclerosing cholangitis….) in immunocompetent patients but also in immunosuppressed 
patients such as in recurrent chronic hepatitis C after liver transplantation.  
There are no specific studies comparing liver biopsy to transient elastography for assessing 
liver fibrosis in patients with chronic renal failure on dialysis. Probably, and by analogy 
with other populations, this could be useful. We must bear in mind that it is more important 
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to establish the fibrosis stage and disregard cirrhosis in such patients, which consequently 
entails a different management of the patient, even though anti-viral treatment is always 
indicated, in order to protect the renal graft after transplantation. In addition, liver biopsy in 
patients on dialysis has a higher morbidity and higher risk of bleeding in comparison to the 
general population. Specific studies well designed to assess the usefulness of elastography 
versus liver biopsy in patients undergoing dialysis would be justified. 
4.2.3.1 Combination of blood test and fibroscan  
Fibroscan can only evaluate tissue elasticity, however when it is combined with blood tests 
and new algorithms it can be indicated in different liver diseases. In the future, new 
formulas combining Fibroscan and diagnostic characteristics will be available for more 
reliable prognosis in different etiologies. A summary of current  methods for assessing 
fibrosis are exposed in Table 4. 
 
CURRENT METHODS FOR ASSESSING FIBROSIS 
INVASIVE 
LIVER 
BIOPSY 
Needs specific preparation and nowadays is only 
indicated in selected patients 
NON-
INVASIVE 
  
Blood/Serum 
markers 
Settings in which 
validation exists 
  APRI AST to platelets ratio Hepatitis B and C 
  Fib-4 
Age,AST,ALT, 
platelets 
Hepatitis C 
  Fibro-Test, 
Alpha2-
macroglobulin, GGT, 
haptoglobin, 
apolipoprotein A1, 
total bilirubin 
Hepatitis B and 
C, alcoholic 
hepatitis, non-
alcoholic fatty 
liver 
  Forns’ Index 
Combination of 
GGT, cholesterol, 
BMI age 
Hepatitis B and C 
IMAGING/SCANNING  TECHNIQUES 
Ultrasonography with Doppler 
analysis 
Identification of portal hypertension. Doppler measures 
velocity of blood flow and hemodynamic variations 
Elastography (Fibroscan), 
Liver stiffness. Not possible if: presence of ascites,  
narrow intercostal spaces,  obesity 
Computed Tomography 
Identifies microvascular changes, but can not be 
performed in renal failure  or in patients who are contrast 
allergic 
Magnetic Resonance 
 
Observes changes in liver parenchyma. Useful studying 
tumours. High cost 
Table 4. Current methods for assessing fibrosis 
4.3 Liver biopsy  
At present, cases with an inconclusive diagnosis can only be resolved by liver biopsy. Liver 
biopsy is considered the “gold standard” for obtaining information concerning the extent of 
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HCV-associated liver disease and further non-suspected diagnosis such as hemosiderosis, 
steatosis, non-alcoholic fatty liver disease etc. Liver biopsy should be carried out in the 
initial study of all patients except in cases of contraindications or clinical and/or 
ultrasonographic established cirrhosis. Desmet et al. (2003a) 
Liver biopsy is an invasive procedure which is associated with an increased risk of bleeding 
in dialysis patients. A liver biopsy may be obtained percutaneously or via the transjugular 
route which is associated with a lower risk. In addition, the transjugular approach can be 
used to measure the hepatic venous pressure gradient and confirm the existence of portal 
hypertension. 
Nowadays, liver biopsy only seems to be mandatory in the evaluation of non-conclusive 
cases. In such cases an assessment of the severity of the liver disease is needed for choosing 
the most suitable treatment. There is an urgent need for non-invasive validated markers of 
hepatic fibrosis in this setting.  
4.3.1 Liver biopsy procedure  
Before the liver biopsy procedure, imaging studies and a detailed coagulation analysis have 
to be performed to investigate hepatobiliary disease. Because of the high risk of bleeding in 
uremic patients, in our unit, liver biopsy is obtained after a dialysis session without heparin. 
An hematocrit at least, of 30% is mandatory; patients whose hematocrit levels are below this 
value receive a blood transfusion. To improve platelet function, a dose of 0.3 mg/kg of body 
weight  of Minurin (Ferring SA, Madrid, Spain) is administered intravenously 30 minutes 
before the biopsy when indicated by hemostatic studies. Transjugular liver biopsy is used in 
patients with platelet levels of less than 100,000/mm3, and a percutaneous approach using a 
needle which is guided by Computed Tomography or Ultrasonography, and not blindly as 
in the past, is indicated in patients with normal coagulation analysis and in those in whom it 
is not necessary to measure portal pression. A better specimen is obtained using this last 
approach.  
4.3.2 Histological assessment 
The primary objective of histologic assessment is to evaluate disease progression in all forms 
of compensated liver disease independently of etiology (viral, toxic, metabolic etc.) and to 
evaluate the extent and type of hepatic fibrosis. Biopsies have to be evaluated by 
experienced pathologists. 
Thus staging of liver fibrosis represents the most useful data for prognosis. Specimens are 
processed with routine stains, hematoxylin and eosin, and connective tissue stains (reticulin 
and trichrome method staining) used for accurate assessment of liver architecture and 
hepatic fibrosis. Specimens are stained by the periodic acid–Schiff method, and the presence 
of hemosiderin in macrophages and Kupffer cells is investigated by Perl’s iron stain method. 
The presence of hepatitis B surface and core antigen is searched for in the cytoplasm and 
nucleus respectively, by immunohistochemistry. If a positive staining for either antigen is 
found, it is indicative of a replicative phase of HBV chronic infection.  
Fat accumulation in hepatocytes (“steatosis”) appears as clearly defined transparent spaces 
within the cytoplasm and can be both macro and microvesicular in nature. Moreover many 
of the liver diseases that contain fat have associated inflammation (e.g. neutrophils in 
alcoholic hepatitis, lymphocytes in chronic viral hepatitis due to HCV infection).  
Pathologists have developed scores for reading and interpreting liver biopsies by sharing 
and correlationing their results with clinical data. Histologic staging (degree of fibrosis) and 
grading (degree of necroinflammatory activity) has become a very useful tool for the 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
240 
clinician when deciding the prognosis and therapeutic options. It is recommended to begin 
the histologic description with the etiology of hepatitis (e. g., chronic hepatitis C) followed 
by the degree of fibrosis, and the degree of activity, with appropriate numerical codes using 
one classification and scoring system. Various scoring systems have been validated for use 
in chronic hepatitis C. Desmet et al. (2003b) 
The most widely used in Europe are METAVIR, Scheuer, Ishak, and Knodell’s Hepatitis 
Activity Index. Metavir and Scheuer’s scores are more reproducible and less prone to 
observer variation, but less discriminant both for fibrosis and for necroinflammation than 
Ishak and Knodell (Table 5). 
 
FIBROSIS STAGE DESCRIPTION CRITERIA 
0 No fibrosis Normal connective tissue
1 Portal fibrosis Fibrous portal expansion
2 Periportal fibrosis 
Periportal or rare portal-
portal septa 
3 Septal fibrosis 
Fibrous septa with 
architectural distortion; 
no obvious cirrhosis 
4 Cirrhosis Cirrhosis 
INFLAMMATORY
GRADE 
DESCRIPTION 
LYMPHOCYTIC 
PIECEMEAL NECROSIS
LOBULAR 
INFLAMMATION 
AND NECROSIS 
0 
Portal 
inflammation 
only; no activity 
None None 
1 Minimal Minimal, patchy 
Minimal, occasional 
spotty necrosis 
2 Mild 
Mild, involving some or 
all portal tracts 
Mild, little 
hepatocellular change 
3 Moderate 
Moderate, involving all 
portal tracts 
Moderate,  
with noticeable 
hepatocellular change 
4 Severe 
Severe, may have 
bridging fibrosis 
Severe, with 
prominent diffuse 
hepatocellular damage 
Table 5. The liver biopsy interpretation in chronic hepatitis: Staging and Grading Systems  
(Batts, 1995, as cited in  Kanel, G. C. & Korula, J.  (2011) Atlas of Liver Pathology) 
In our unit, biopsies are scored according to the classical system proposed by Scheuer, in 
which necroinflammatory activity (portal/periportal hepatitis and lobular activity) and 
fibrosis are evaluated separately, and are classified on a scale of a 0-4, as follows: F0, no 
fibrosis; F1, portal fibrosis; F2, periportal fibrosis; F3, septal fibrosis; and F4, cirrhosis 
based on the recommended criteria. Bile duct and cholangiolar proliferation may be 
present but are not prominent, except in instances of severe liver cell injury. Other 
findings such as iron deposits are studied in Kupffer and liver cells and are classified as 
mild, moderate, or severe. But over the years, steatosis, non-alcoholic fatty liver, has 
become more important.  
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Liver biopsy provides information regarding the presence or absence of cirrhosis especially 
if a study of portal pression is incorporated to the procedure. In the cirrhotic stage, the 
regenerative nodules are often “macronodular”, more than 3 mm. If they are less than 3 mm, 
they are micronodular. Sometimes a mixed pattern with both macro and micronodules can 
be detected. 
Recently, the great advances in radiological imaging techniques have focused attention on 
hepatic premalignant nodular lesions. The histological differential diagnosis of these 
nodules can often be difficult, especially in needle biopsy specimens with limited material. 
Diagnostic considerations differ significantly between livers with and without cirrhosis: In 
the noncirrhotic liver, the differential diagnosis includes liver cell adenoma, nodular 
regenerative hyperplasia, and hepatocellular carcinoma. In cirrhosis, dysplastic nodules 
(low and high grade), dysplasia (large and small cell) as well as hepatocellular carcinoma 
may occur. The standardization and the uniform use of the nomenclature of these entities 
are necessary for a better understanding of the biological nature and etiopathology of these 
lesions. Only a commonly accepted nomenclature makes a comparison of different 
therapeutic treatment regimens feasible. 
Liver biopsy also assesses the disease severity by evaluating the parenchyma structure and 
other possible tissue damage related to non-suspected lesions. It helps to determine the 
degree of disease progression, the need for anti-viral treatment, patient motivation and the 
indication of a combined liver and kidney transplant. 
4.3.3 Diagnosis of hepatic fibrosis and cirrhosis 
Cirrhosis can be defined as the end stage consequence of fibrosis of the hepatic parenchyma 
resulting in nodule formation and altered hepatic function.  
Up to 40% of patients with cirrhosis are asymptomatic and may remain so for more than a 
decade, but progressive deterioration is inevitable once complications develop, including 
ascites, variceal hemorrhage or encephalopathy. Early diagnosis of liver cirrhosis in chronic 
hepatitis patients is critical in its management. All cirrhotic patients, notably after solid 
organ transplantation, should be screened for hepatocellular carcinoma. Liver biopsy 
increases costs and has potential risks, however, diagnosis of compensated liver cirrhosis 
usually requires doing a liver biopsy and assessment of portal hypertension 
(fibrosgastroscopy and direct measurement). Liver biopsy is the most accurate diagnostic 
method in the diagnosis of compensated liver cirrhosis, but a liver biopsy is performed in 
few patients in clinical practice. 
Complications in the general population are very low (1/4000–10,000), but the risk of 
hemorrhage in uremics has to be taken into account, false negative probability due to 
sampling error is reported to be of 20 to 30%. A liver specimen obtained to be evaluated has 
to be more than 1 cm in length.  
For these reasons, nowadays it is necessary to establish non-invasive diagnostic methods, 
validated predominantly for chronic HCV, to allow for an easier diagnosis of liver cirrhosis 
in different populations. 
4.3.4 Liver biopsy data in dialysis patients  
A few researchers have evaluated histologic severity of liver disease in HCV-positive 
patients with end stage renal disease. Martin et al., (2000) reported 37 anti-HCV positive 
patients, who were referred for renal transplant, most of whom were already dialysis 
dependent and had undergone liver biopsy. Mild or moderate necroinflammatory activity 
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occurred in all patients; bridging fibrosis was present in 3 of 37 (8%), and frank cirrhosis in 9 
(24%). No relationship between severity of histologic changes and HCV viral load or 
genotype or ALT activity was reported. In this study, a history of alcohol abuse was elicited 
in 38% of patients, perhaps accounting in part for the frequency of advanced fibrosis.  
Sterling et al., (1999) evaluated liver histology in 50 consecutive patients with chronic HCV 
awaiting renal transplantation. Bridging fibrosis or cirrhosis was present in 22%, which was 
not significantly different from a control group of HCV-positive patients with intact renal 
function and normal ALT, although there was a trend toward more fibrosis in the dialysis 
group.  
The impact of renal transplantation on the natural history of HCV infection has been shown 
by Zylberberg et al. In a case-control study including 28 kidney transplanted HCV-infected 
patients compared with 28 matched immunocompetent controls, they observed 
histopathological deterioration in 70% of the transplanted patients compared to 19% of the 
controls. The median time elapsed between kidney transplantation and the final liver biopsy 
in the study was 13.6 years (range 2.6–23.9 years). The progressive nature of liver disease in 
HCV-infected renal transplanted recipients is probably related to numerous factors. There is 
evidence that acute HCV acquired perioperatively acts more aggressively in such patients, 
perhaps reflecting an acute infection at the time the patient is receiving maximum 
immunosuppression. It appears that therapeutic immunosuppression following renal 
transplant may accelerate the course of HCV infection leading to hepatocellular failure. On 
the other hand, the overall survival advantage conferred by transplant may outweigh the 
potential negative effects of immunosuppression for many renal transplant patients.  
5. Impact of viral eradication on mortality related to hepatitis  
Despite the fact that HCV and HBV infections adversely affect the survival of dialysis and 
renal transplant patients and its high prevalence in these groups of patients, large clinical 
trials are rare. 
5.1 Hemodialysis patients  
Due to the negative long-term impact of HCV infection after transplantation and to the 
current lack of treatment options for HCV after kidney transplantation, treatment of 
haemodialysis patients should be attempted when possible. 
Careful patient selection and side effect management are important. Combination treatment 
with pegylated interferon and ribavirin might be considered by experienced physicians, 
with individualized ribavirin dosing and substantial hematopoietic support, as suggested 
by few preliminary studies.  
The optimal treatment of HCV in dialysis patients and a more in depth profile of patients 
has not been determined. We perform Electroencephalography, and echocardiography in 
order to be aware of unexpected risks and therefore be able to prevent them. 
5.2 Therapeutic options after kidney transplant   
Although treatment of kidney transplants recipients who have hepatitis C is not routinely 
recommended because of the potential risk for precipitating rejection, some clinical 
presentations warrant consideration of interferon-based therapy. The most pressing reasons 
to consider HCV therapy are recurrent and progressive HCV-associated glomerulopathy in 
the transplanted kidney, severe cholestatic hepatitis, and advanced histologic stages of liver 
disease. 
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5.3 HCV-mediated glomerulonephritis  
 HCV-mediated glomerulonephritis may be effectively managed with interferon-based 
therapy. The current “best therapy” for these situations is combination therapy with 
interferon and ribavirin, because combination therapy is the most likely to achieve a 
sustained viral response.  
6. Algorithms and new perspectives 
Although practices regarding whether patients with cirrhosis should be referred for 
combined liver and kidney transplantation or whether they should be considered for kidney 
transplantation alone vary by center, an algorithm for assessment of the fibrosis stage or 
presence of cirrhosis and evaluation for anti– hepatitis C treatment may be suggested. 
By adding non invasive methods such as Fibroscan to the routine tests (abdominal 
ultrasonography with Doppler and blood analysis) liver biopsy may be avoided in the 
majority of cases and it could be indicated only when there is a discrepancy between clinical 
and analytical data. 
Patients with liver cirrhosis with portal hypertension, and who had some liver 
decompensation do not need liver biopsy and have to be considered candidates to combined 
liver and kidney transplant while patients with cirrhosis or advanced fibrosis should 
undergo more in depth studies. 
7. Conclusion 
- At present, Hepatitis C and B infection represent a major medical and epidemiologic 
challenge both in patients on renal replacement therapy and patients undergoing 
kidney transplantation. The major concern, however, is the lack of safe and effective 
drugs to treat HCV-infected patients with chronic kidney disease.   
- Unfortunately, there have not been any large scale clinical trials performed on this 
population, therefore the evidence for treatment recommendations is scant and the role 
of liver biopsy in selected cases is vigent. 
- Assessment of the severity of liver fibrosis is important in decision making in patients 
with chronic hepatitis C under dialysis which is why liver biopsy is still regarded as the 
reference method to assess the grade of inflammation and the stage of fibrosis. Patients 
on dialysis, even those diagnosed with chronic hepatitis, have the possibility to receive 
a  kidney transplant, which may have a more favourable evolution if prior to transplant 
viral eradication is achieved. Another concern in patients also suffering from chronic 
liver disease is deciding whether they will only need a kidney transplant or whether a 
combined kidney and liver transplantation is necessary. 
- Until recently, a combined transplant was always recommended for patients with 
advanced fibrosis or cirrhosis. However, nowadays due to a lack of donors, in some 
centers, patients are only being referred for a kidney transplant, providing that the 
patient has   never suffered from decompensated liver disease. 
- Furthermore, in recent years transient elastography (Fibroscan) has been progressively 
introduced in order to resolve diagnosis uncertainty regarding the  fibrosis stage in 
different clinical settings, especially  in patients with chronic hepatitis C due to its high 
prevalence worldwide, but it has not been validated for kidney patients yet. 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
244 
- In kidney transplant recipients, HCV infection is associated with an increased risk of de 
novo glomerulonephritis and liver-related mortality, both HCV related.  
- In conclusion, as cirrhosis is an important predictor of poor post-kidney transplant 
survival after kidney transplantation, it is advisable to obtain a liver biopsy from 
selected HCV-positive kidney transplant candidates, considering that the combination 
of common blood tests, abdominal echography and Fibroscan  can improve accuracy 
and reduce the necessity of using liver biopsy.  
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